Patents by Inventor Birger Sorensen
Birger Sorensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230109142Abstract: The present invention relates to the field of virus immunotherapy. In particular the present invention relates to novel peptides and methods for treatment, induction of immunity, prophylaxis and amelioration of a disease caused by virus infections with Corona virus, in particular Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1.Type: ApplicationFiled: February 15, 2021Publication date: April 6, 2023Applicant: Immunor ASInventors: Andres Schjønhaug Susrud, Birger Sørensen, Samara Simha Mamidi, Richard Escobar Johnsson
-
Patent number: 10501499Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, HPV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: GrantFiled: June 6, 2013Date of Patent: December 10, 2019Assignee: BIONOR IMMUNO ASInventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold
-
Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
Patent number: 10335482Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilization of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.Type: GrantFiled: June 6, 2013Date of Patent: July 2, 2019Assignee: BIONOR IMMUNO ASInventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen -
Patent number: 10251949Abstract: Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.Type: GrantFiled: November 25, 2015Date of Patent: April 9, 2019Assignee: BIONOR IMMUNO ASInventors: Maja Sommerfelt Grønvold, Angus Dalgleish, Einar Tønnes Lange, Jens Olof Holmberg, Per Bengtsson, Birger Sørensen
-
Patent number: 10124059Abstract: The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: GrantFiled: September 14, 2016Date of Patent: November 13, 2018Assignee: BIONOR IMMUNO ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Birger Sørensen, Karolina Lawitz
-
Publication number: 20170112917Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: ApplicationFiled: December 21, 2016Publication date: April 27, 2017Applicant: Bionor Immuno ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Jens Olof Holmberg, Birger Sørensen
-
Patent number: 9550811Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: GrantFiled: December 2, 2011Date of Patent: January 24, 2017Assignee: BIONOR IMMUNO ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Jens Olof Holmberg, Birger Sørensen
-
Publication number: 20160375129Abstract: The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: ApplicationFiled: September 14, 2016Publication date: December 29, 2016Applicant: BIONOR IMMUNO ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Birger Sørensen, Karolina Lawitz
-
Patent number: 9493514Abstract: The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: GrantFiled: January 6, 2012Date of Patent: November 15, 2016Assignee: BIONOR IMMUNO ASInventors: Einar Tonnes Lange, Maja Sommerfelt Gronvold, Birger Sorensen, Karolina Lawitz
-
Publication number: 20160144019Abstract: Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.Type: ApplicationFiled: November 25, 2015Publication date: May 26, 2016Applicant: Bionor Immuno ASInventors: Maja Sommerfelt GRØNVOLD, Angus DALGLEISH, Einar Tønnes LANGE, Jens Olof HOLMBERG, Per BENGTSSON, Birger SØRENSEN
-
Patent number: 9200065Abstract: Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.Type: GrantFiled: July 3, 2010Date of Patent: December 1, 2015Assignee: Bionor Immuno ASInventors: Maja Sommerfelt Grønvold, Angus Dalgleish, Einar Tønnes Lange, Jens Olof Holmberg, Per Bengtsson, Birger Sørensen
-
Publication number: 20150174235Abstract: The present invention relates to novel combinations of active agents and methods for treatment of retrovirus infections including HIV infections and AIDS. In particular, the present invention relates to novel use of administrations and combinations of a compound to stimulate the humoral immunity and/or peptides that elicit a cell-mediated immune response in a subject; and immunomodulatory compounds and/or a reservoir purging agent, such as a histone deacetylase (HDAC) inhibitor.Type: ApplicationFiled: June 6, 2013Publication date: June 25, 2015Inventors: Lars Hoie, Anker Lundemose, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Vidar Wendel Hansen, Birger Sorensen
-
Publication number: 20150152140Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, HPV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: ApplicationFiled: June 6, 2013Publication date: June 4, 2015Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold
-
Publication number: 20150132255Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.Type: ApplicationFiled: June 6, 2013Publication date: May 14, 2015Applicant: Bionor Immuno ASInventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
-
Publication number: 20140044746Abstract: The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: ApplicationFiled: January 6, 2012Publication date: February 13, 2014Applicant: BIONOR IMMUNO ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Birger Sørensen, Karolina Lawitz
-
Publication number: 20130337002Abstract: The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.Type: ApplicationFiled: December 2, 2011Publication date: December 19, 2013Applicant: BIONOR IMMUNO ASInventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Jens Olof Holmberg, Birger Sørensen
-
Publication number: 20120263720Abstract: Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gp120 and on the other hand gp41 or the C2 domain of gp120. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.Type: ApplicationFiled: July 3, 2010Publication date: October 18, 2012Applicant: Bionor Immuno ASInventors: Maja Sommerfelt Grønvold, Angus Dalgleish, Einar Tønnes Lange, Jens Olof Holmberg, Per Bengtsson, Birger Sørensen
-
Publication number: 20100330612Abstract: The present invention relates to a substrate for measuring the electrophysiological properties of ion-channels located in cell membranes. The substrate is typically used in a screening device providing high-throughput industrialized measurements for studying ionic currents, particularly useful in the screening of drugs acting on the ion-channels found in cell membranes, by providing many parallel simultaneous and independent measurements. The substrate has one or a plurality of individually addressable electrode sites, each comprising one or more individual elongated nanosize electrodes, capable of penetrating the cell membranes during application of cells directly on the substrate, thus providing one or more low resistance contacts to the interior of the cells. This allows for an easy and effective low-cost solution to automated patch clamp measurements in the whole-cell configuration, using both single as well as multi-electrode contacts to each cell.Type: ApplicationFiled: February 21, 2008Publication date: December 30, 2010Applicant: Inxell Bionics ApSInventor: Claus Birger Sorensen
-
Patent number: 7709004Abstract: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.Type: GrantFiled: October 1, 2007Date of Patent: May 4, 2010Assignee: Bionor Immuno ASInventor: Birger Sörensen
-
Patent number: 7709003Abstract: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.Type: GrantFiled: October 1, 2007Date of Patent: May 4, 2010Assignee: Bionor Immuno ASInventor: Birger Sörensen